FDA granted accelerated approval to Tudriqev with nivolumab for advanced melanoma after two rejections. Who qualifies and what evidence is still owed.
FDA Approves Replimune’s Tudriqev for Advanced Melanoma After Two Previous Rejections
by | Aug 8, 2026 | Uncategorized | 0 comments
Recent Comments